The Globe and Mail recently profiled Royal Bank of Canada's undisclosed investment in the country’s largest life sciences venture capital fund in two decades. Lumira is raising its fourth fund with a target of reaching US$200-million to back Canadian and U.S. drug and medical technology developers.